Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: In addition to the globally endorsed Barcelona Clinic Liver Cancer (BCLC) staging system, other algorithms or staging systems have been developed, including the Hong Kong Liver Cancer (HKLC) staging system. This study aimed to validate the HKLC staging system relative to the BCLC staging system for predicting survival for hepatocellular carcinoma (HCC) patients in Korea. Methods: From 2004 to 2013, 2,571 patients newly diagnosed with HCC were consecutively enrolled at three Korea University medical centers. Results: Both staging systems differentiated survival well (p<0.001). However, 1-year and 3-year survival were predicted better using the HKLC system than the BCLC system (area under the receiver operating characteristic curve: 0.869 vs 0.856 for 1 year, p=0.002; 0.841 vs 0.827 for 3 years, p=0.010). In hypothetical survival curves, the HKLC system exhibited better median overall survival than the BCLC system (33.1 months vs 19.2 months). In evaluations of prognosis according to either BCLC or HKLC treatment guidelines, risk of death was reduced in the group following only HKLC guidelines compared with the group following only BCLC guidelines (hazard ratio, 0.601; 95% confidence interval, 0.443 to 0.816; p=0.001). Conclusions: Although both staging systems predicted and discriminated HCC prognoses well, the HKLC system showed more encouraging survival benefits than the BCLC system.
Abstract
Background/Aims: In addition to the globally endorsed Barcelona Clinic Liver Cancer (BCLC) staging system, other algorithms or staging systems have been developed, including the Hong Kong Liver Cancer (HKLC) staging system. This study aimed to validate the HKLC staging system relative to the BCLC staging system for predicting survival for hepatocellular carcinoma (HCC) patients in Korea. Methods: From 2004 to 2013, 2,571 patients newly diagnosed with HCC were consecutively enrolled at three Korea University medical centers. Results: Both staging systems differentiated survival well (p<0.001). However, 1-year and 3-year survival were predicted better using the HKLC system than the BCLC system (area under the receiver operating characteristic curve: 0.869 vs 0.856 for 1 year, p=0.002; 0.841 vs 0.827 for 3 years, p=0.010). In hypothetical survival curves, the HKLC system exhibited better median overall survival than the BCLC system (33.1 months vs 19.2 months). In evaluations of prognosis according to either BCLC or HKLC treatment guidelines, risk of death was reduced in the group following only HKLC guidelines compared with the group following only BCLC guidelines (hazard ratio, 0.601; 95% confidence interval, 0.443 to 0.816; p=0.001). Conclusions: Although both staging systems predicted and discriminated HCC prognoses well, the HKLC system showed more encouraging survival benefits than the BCLC system.
참고문헌 (24)
- Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)[DOI]
- Meier V, "Clinical staging of hepatocellular carcinoma", Dig Dis, 27, pp.131~141 (2009)[DOI]
- Edge SB, "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)[DOI]
- Yau T, "Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma", Gastroenterology, 146, pp.1691~1700 (2014)[DOI]
- Sanyal AJ, "The etiology of hepatocellular carcinoma and consequences for treatment", Oncologist, 15(Suppl 4), pp.14~22 (2010)[DOI]
- Fattovich G, "Hepatocellular carcinoma in cirrhosis: incidence and risk factors", Gastroenterology, 127(5 Suppl 1), pp.S35~S50 (2004)[DOI]
- El-Serag HB, "Hepatocellular carcinoma: epidemiology and molecular carcinogenesis", Gastroenterology, 132, pp.2557~2576 (2007)[DOI]
- Lin CL, "Risk stratification for hepatitis B virus related hepatocellular carcinoma", J Gastroenterol Hepatol, 28, pp.10~17 (2013)[DOI]
- Chan SL, "Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population", J Gastroenterol Hepatol, 26, pp.340~347 (2011)[DOI]
- Hsu CY, "Aggressive therapeutic strategies improve the survival of hepatocellular carcinoma patients with performance status 1 or 2: a propensity score analysis", Ann Surg Oncol, 22, pp.1324~1331 (2015)
- 김준영, "Transarterial chemoembolization versus resection for the intermediate stage hepatocellular carcinoma", Clinical and Molecular Hepatology, 22(2), pp.250~258 (2016), 대한간학회
- 이정민, "Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis", Clinical and Molecular Hepatology, 22(1), pp.160~167 (2016), 대한간학회
- Llovet JM, "Prognosis of hepatocellular carcinoma: the BCLC staging classification", Semin Liver Dis, 19, pp.329~338 (1999)[DOI]
- Adhoute X, "Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort", J Hepatol, 62, pp.492~493 (2015)[DOI]
- Yan X, "Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort", Eur J Gastroenterol Hepatol, 27, pp.1180~1186 (2015)[DOI]
- Liu PH, "Hong Kong Liver Cancer staging system is associated with better performance for hepatocellular carcinoma: special emphasis on viral etiology", Medicine (Baltimore), 94, pp.e1772~ (2015)[DOI]
- Franssen B, "Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center", Ann Surg, 260, pp.650~656 (2014)[DOI]
- Hiotis SP, "Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma", BMC Gastroenterol, 12, pp.64~ (2012)[DOI]
- Miao RY, "Postoperative adjuvant antiviral therapy for hepatitis B", C virus-related hepatocellular carcinoma: a meta-analysis, 2010, pp.16, 2931~2942
- Ferenci P, "HCV targeting of patients with cirrhosis", J Hepatol, 63, pp.1015~1022 (2015)[DOI]
- Bolondi L, "Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions", Semin Liver Dis, 32, pp.348~359 (2012)
- Gao Q, "Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery", Nat Rev Clin Oncol, 12, pp.10~ (2015)[DOI]
- Forner A, "Reply: heterogeneity of intermediate-stage HCC necessitates personalized management including surgery", Nat Rev Clin Oncol, 12, pp.10~ (2015)[DOI]
- Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study", Liver Int, 35, pp.2155~2166 (2015)[DOI]